Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
IPInnate Pharma S.A. logo

Innate Pharma S.A. (IPHA)

NASDAQ Global Select · Currency in USD
$1.50 ▲ +0.00 (+0.00%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.45 ▼ -0.05 (-3.23%)
After hours: Oct 23, 6:48 PM ET

Summary

Previous Close
$1.50
Open
$1.50
Day's Range
$1.48 – $1.52
52 Week Range
$1.17 – $2.71
Volume
11,621
Avg. Volume
120,753
Market Cap
$163.38M
Beta (5Y Monthly)
0.88
PE Ratio (TTM)
--
EPS (TTM)
-$0.51
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$6.67

Profile: Innate Pharma S.A.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
163
CEO
Jonathan E. Dickinson

Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome.

Earnings

DateEst.Actual
Sep 17, 2026-$0.29-$0.24Beat
May 13, 2026-$0.35-$0.35Beat
Nov 13, 2025-$0.33-$0.30Beat
May 13, 2025-$0.27-$0.35Miss
Nov 13, 2024-$0.30-$0.34Miss
May 14, 2024-$0.44-$0.13Beat

Analyst view

Consensus price target
$6.67 ▲ +344.7%
Range $4.00 – $9.00
Rating: Buy
Buy 67% · Hold 33% · Sell 0%

Get free alerts on IPHA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.